Gene therapy targeted to Flt3L and HSV1-TK in combination with a DCV can improve antitumor immunity, therapeutic efficacy and long-term survival by modifying the brain TME in a syngeneic glioma model 120. The gene discussed is TKT; the disease is glioma.